UBS Initiates Coverage On Biohaven with Buy Rating, Announces Price Target of $59
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma initiates coverage on Biohaven (NYSE:BHVN) with a Buy rating and a price target of $59.

February 06, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS initiates coverage on Biohaven with a Buy rating and a price target of $59.
The initiation of coverage by a major financial institution like UBS, especially with a Buy rating and a significant price target, is typically seen as a positive signal to the market. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100